Cargando…

Benefits of Sustained Upregulated Unimolecular GLP-1 and CCK Receptor Signalling in Obesity-Diabetes

Combined activation of GLP-1 and CCK1 receptors has potential to synergistically augment the appetite-suppressive and glucose homeostatic actions of the individual parent peptides. In the current study, pancreatic beta-cell benefits of combined GLP-1 and CCK1 receptor upregulation were established,...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tanday, Neil, English, Andrew, Lafferty, Ryan A., Flatt, Peter R., Irwin, Nigel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8160446/ https://www.ncbi.nlm.nih.gov/pubmed/34054734 http://dx.doi.org/10.3389/fendo.2021.674704

Ejemplares similares

Metabolic responses and benefits of glucagon‐like peptide‐1 (GLP‐1) receptor ligands
por: Tanday, Neil, et al.
Publicado: (2021)

Positive Effects of NPY1 Receptor Activation on Islet Structure Are Driven by Pancreatic Alpha- and Beta-Cell Transdifferentiation in Diabetic Mice
por: Lafferty, Ryan A., et al.
Publicado: (2021)

Beneficial metabolic effects of recurrent periods of beta‐cell rest and stimulation using stable neuropeptide Y1 and glucagon‐like peptide‐1 receptor agonists
por: Tanday, Neil, et al.
Publicado: (2022)

Beneficial impact of Ac3IV, an AVP analogue acting specifically at V1a and V1b receptors, on diabetes islet morphology and transdifferentiation of alpha- and beta-cells
por: Mohan, Shruti, et al.
Publicado: (2021)

The GLP-1 Receptor Agonist Exenatide Ameliorates Bone Composition and Tissue Material Properties in High Fat Fed Diabetic Mice
por: Mansur, Sity Aishah, et al.
Publicado: (2019)

A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice
por: Hornigold, David C., et al.
Publicado: (2018)

CCK‐1 and CCK‐2 receptor agonism do not stimulate GLP‐1 and neurotensin secretion in the isolated perfused rat small intestine or GLP‐1 and PYY secretion in the rat colon
por: Modvig, Ida M., et al.
Publicado: (2020)

Proglucagon-Derived Peptides as Therapeutics
por: Lafferty, Ryan A., et al.
Publicado: (2021)

GLP−1 receptor agonists for the treatment of obesity: Role as a promising approach
por: Wang, Jing-Yue, et al.
Publicado: (2023)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Cholecystokinin (CCK) and its receptors (CCK1R and CCK2R) in chickens: functional analysis and tissue expression
por: Wan, Yiping, et al.
Publicado: (2022)

Unimolecular reactions
por: Holbrook, Kenneth A.
Publicado: (1996)

Discovery of a Positive Allosteric Modulator of Cholecystokinin Action at CCK1R in Normal and Elevated Cholesterol
por: Harikumar, Kaleeckal G., et al.
Publicado: (2021)

Regulation of mammalian gastrin/CCK receptor (CCK2R) expression in vitro and in vivo
por: Ashurst, H Louise, et al.
Publicado: (2008)

Radiolabeled CCK/gastrin peptides for imaging and therapy of CCK2 receptor-expressing tumors
por: Roosenburg, Susan, et al.
Publicado: (2010)

Sustained glucagon receptor antagonism in insulin-deficient high-fat-fed mice
por: Lafferty, Ryan A, et al.
Publicado: (2022)

Clinical perspectives on the use of the GIP/GLP-1 receptor agonist tirzepatide for the treatment of type-2 diabetes and obesity
por: Gallwitz, Baptist
Publicado: (2022)

GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects
por: Zhao, Xin, et al.
Publicado: (2021)

Intra-islet GLP-1, but not CCK, is necessary for β-cell function in mouse and human islets
por: de Souza, Arnaldo Henrique, et al.
Publicado: (2020)

Behavioural and neurochemical mechanisms underpinning the feeding-suppressive effect of GLP-1/CCK combinatorial therapy
por: Roth, Emma, et al.
Publicado: (2020)

GLP-1 based therapeutics: simultaneously combating T2DM and obesity
por: Heppner, Kristy M., et al.
Publicado: (2015)

CCK2 receptors in chronic pain
por: LaVigne, Justin E., et al.
Publicado: (2022)

Sex-based impact of pancreatic islet stressors in Glu(CreERT2)/Rosa26-eYFP mice
por: Tanday, Neil, et al.
Publicado: (2023)

A walnut-containing meal had similar effects on early satiety, CCK, and PYY, but attenuated the postprandial GLP-1 and insulin response compared to a nut-free control meal
por: Rock, Cheryl L., et al.
Publicado: (2017)

Impact of GLP-1 receptor agonist versus omega-3 fatty acids supplement on obesity-induced alterations of mitochondrial respiration
por: Jansen, Kirsten M., et al.
Publicado: (2023)

Stearic acid induces CCK and GLP-1 upregulation via GPR120/PLC-β, leading to reduced appetite in Hu sheep fed with rice straw
por: Chen, Xi, et al.
Publicado: (2022)

The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer’s disease
por: Du, Haiyang, et al.
Publicado: (2022)

Unimolecular reaction dynamics : theory and experiments
por: Baer, Tomas
Publicado: (1996)

Striking the Balance: GLP-1/Glucagon Co-Agonism as a Treatment Strategy for Obesity
por: Hope, David C. D., et al.
Publicado: (2021)

CCK Stimulation of GLP-1 Neurons Involves α(1)-Adrenoceptor–Mediated Increase in Glutamatergic Synaptic Inputs
por: Hisadome, Kazunari, et al.
Publicado: (2011)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP‐1 but not GIP, CCK, and gastrin in plasma
por: Asmar, Ali, et al.
Publicado: (2020)

[Gly²]-GLP-2, But Not Glucagon or [D-Ala²]-GLP-1, Controls Collagen Crosslinking in Murine Osteoblast Cultures
por: Mieczkowska, Aleksandra, et al.
Publicado: (2021)

Adolescents with obesity treated with exenatide maintain endogenous GLP-1, reduce DPP-4, and improve glycemic control
por: Stenlid, Rasmus, et al.
Publicado: (2023)

Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System
por: Puglisi, Soraya, et al.
Publicado: (2021)

Systems-Level G Protein-Coupled Receptor Therapy Across a Neurodegenerative Continuum by the GLP-1 Receptor System
por: Janssens, Jonathan, et al.
Publicado: (2014)

SUN-544 Immunologic Effects of GLP-1 Activation in Obese Adipose Tissue
por: Mashayekhi, Mona, et al.
Publicado: (2020)

Increased Body Weight and Fat Mass After Subchronic GIP Receptor Antagonist, but Not GLP-2 Receptor Antagonist, Administration in Rats
por: Baldassano, Sara, et al.
Publicado: (2019)

Upregulation of Oxytocin Receptor in the Hyperplastic Prostate
por: Li, Zhuo, et al.
Publicado: (2018)

Supplementation with a fish protein hydrolysate (Micromesistius poutassou): effects on body weight, body composition, and CCK/GLP-1 secretion
por: Nobile, Vincenzo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_g1lm8hh796kp8g0v0g4qtj707h